SWOG clinical trial number
SWOG-9207

Phase II Trial of Edatrexate Plus Carboplatin in Metastatic Non-Small Cell Lung Cancer

Closed
Phase
Accrual
62%
Published
Abbreviated Title
Phase II Trial of Edatrexate Plus Carboplatin in Metastatic Non-Small Cell Lung Cancer
Activated
01/01/1993
Closed
06/01/1995

Research committees

Lung Cancer

Publication Information Expand/Collapse

1997

Phase II trial of edatrexate plus carboplatin in metastatic non-small cell lung cancer: A Southwest Oncology Group study.

DR Gandara;MJ Edelman;JJ Crowley;RB Livingston Cancer Chemotherapy and Pharmacology 41:75-78

1996

Edatrexate and carboplatin in stage IV non-small cell lung cancer: Phase II trial of the Southwest Oncology Group (SWOG).

D Gandara;M Edelman;G Smith;J Crowley;R Livingston American Society of Clinical Oncology 15:397(#1202)

Other Clinical Trials

SWOG Clinical Trial Number
A082302

EVALUATING ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS TO PREVENT RECURRENCE IN STAGE I NON-SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE III TRIAL (AASI-NSCLC)
Research Committee(s)
Lung Cancer
Activated
03/02/2027
Open
SWOG Clinical Trial Number
S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase